Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of next-generation synthetic binders for the life sciences industry, has announced that Twist Bioscience Corporation has launched its new TrueAmp Library Preparation Kit, which uses Aptamer’s proprietary Optimer® binders as an enabling technology for stability at room temperature, within the TrueAmp Library Preparation Kit¹.

Product Launch

The TrueAmp Library Preparation Kit represents a significant advancement in next-generation sequencing (NGS) library amplification workflows. By using Aptamer’s Optimer® binders, the Twist TrueAmp Library Prep Kit delivers a new level of exceptional performance to Twist’s library preparation portfolio. These advantages are enabled by Twist’s in-house developed enzymes, including a previously developed ligase and a newly developed polymerase.

Engineered for NGS applications, the specialised TrueAmp polymerase maximises coverage across typically hard-to-sequence regions of the genome – while maintaining high accuracy during DNA copying. The kit delivers high yields even from low-input or degraded starting samples, which minimises amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep Kit has been validated with the Twist HT-UDI adapter system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing.  

Partnership Background

As announced in December 2025,2 Aptamer issued a non-exclusive license to Twist Bioscience for the use of the Optimer inhibitor for a proprietary high-fidelity polymerase.

This partnership strategically combines Twist Bioscience’s expertise in synthetic biology and genomics with Aptamer’s pioneering Optimer® binder technology to create solutions for the rapidly expanding next-generation sequencing market.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: “We are delighted to play a small but significant part in Twist Bioscience bringing the TrueAmp Library Preparation Kit to market. This product launch demonstrates the real-world value of our Optimer® technology in enabling market-ready products.

In this hot-start PCR application, the Optimer® binder demonstrates robust performance, eliminating the need for two separate antibody reagents typically required in alternative methods. We look forward to the continued success of our collaboration with Twist Bioscience and the transformative impact this product will have in advancing genomics research and clinical applications.”

1.    TrueAmp Library Preparation Kit

1.    Twist Bioscience Launches Next Generation Library Preparation Kits Powered by Proprietary Enzymes

2.    Aptamer signs licensing agreement with Twist Bioscience

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue 45.7 million shares at 0.6p each, bringing total gross proceeds from the placing, subscription and retail offer to about £4.5 million.

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed.

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028.

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches.

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

    Search